https://aijourn.com/energenesis-biomedical-announces-positive-phase-i-results-for-energi-f705pd-a-potential-disease-modifying-treatment-for-parkinsons-disease/
TAIPEI, Aug. 1, 2025 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company focused on cellular energy
energenesisbiomedicalannouncespositivephase